glp 1 shortage update GLP-1 use: More people without diabetes use drugs for weight loss PDF) Addressing the Shortage of

Long-acting formulations aim to enhance bioavailability, reduce adverse events, and prolong therapeutic duration (Rosenstock et al., 2023

0.9999 for S123G and V214A in panel c (activation rate)

The press release compares this to DHT-semaglutides AE rate of 79.2%

Duplicate entries were resolved through a two-step deduplication protocol 20 : 1) retaining the most recent FDA receipt date (FDA_DT) for identical CASEID entries

Eloralintide (LY3841136): A Selective Amylin Receptor Agonist Eli Lilly also shared Phase 1 data on Eloralintide (LY3841136), a selective amylin receptor agonist that mimics the natural hormone amylin to regulate appetite and blood glucose